Endo International PLC
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. It operates in four segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. The company offers branded pharmaceuticals, including XIAFLEX to treat adult patients with Dupuytren's… Read more
Endo International PLC (0Y5F) - Net Assets
Latest net assets as of December 2023: $-6.60 Billion USD
Based on the latest financial reports, Endo International PLC (0Y5F) has net assets worth $-6.60 Billion USD as of December 2023.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($5.14 Billion) and total liabilities ($11.73 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-6.60 Billion |
| % of Total Assets | -128.42% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | -373.96% |
| Growth Volatility | 168.93 |
Endo International PLC - Net Assets Trend (2012–2023)
This chart illustrates how Endo International PLC's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Endo International PLC (2012–2023)
The table below shows the annual net assets of Endo International PLC from 2012 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $-6.60 Billion | -58.51% |
| 2022-12-31 | $-4.16 Billion | -234.58% |
| 2021-12-31 | $-1.24 Billion | -91.99% |
| 2020-12-31 | $-647.94 Million | +25.23% |
| 2019-12-31 | $-866.54 Million | -73.91% |
| 2018-12-31 | $-498.28 Million | -202.76% |
| 2017-12-31 | $484.88 Million | -82.05% |
| 2016-12-31 | $2.70 Billion | -54.73% |
| 2015-12-31 | $5.97 Billion | +147.82% |
| 2014-12-31 | $2.41 Billion | +311.51% |
| 2013-12-31 | $585.22 Million | -48.36% |
| 2012-12-31 | $1.13 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Endo International PLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1991.9% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $68.00K | % |
| Other Comprehensive Income | $-223.76 Million | % |
| Other Components | $8.98 Billion | % |
| Total Equity | $-6.60 Billion | 100.00% |
Endo International PLC Competitors by Market Cap
The table below lists competitors of Endo International PLC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Castillo Copper Ltd
AU:CCZ
|
$9.90 Million |
|
BTC Digital Ltd.
NASDAQ:BTCT
|
$9.90 Million |
|
SONOKONG Co. Ltd
KQ:066910
|
$9.90 Million |
|
Ovaro Kiinteistosijoitus Oyj
HE:OVARO
|
$9.90 Million |
|
All In! Games S.A.
WAR:ALG
|
$9.90 Million |
|
INVENIA Co. Ltd
KQ:079950
|
$9.89 Million |
|
DEXIN CHINA HLD. DL-0005
F:26X
|
$9.88 Million |
|
SAGTEC GLOBAL LIMITED Ordinary shares
NASDAQ:SAGT
|
$9.88 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Endo International PLC's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from -4,162,172,000 to -6,597,560,000, a change of -2,435,388,000.
- Net loss of 2,449,807,000 reduced equity.
- Other comprehensive income increased equity by 3,179,000.
- Other factors increased equity by 11,240,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-2.45 Billion | -37.13% |
| Other Comprehensive Income | $3.18 Million | +0.05% |
| Other Changes | $11.24 Million | +0.17% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Endo International PLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $9.27 | $909.43 | x |
| 2013-12-31 | $4.39 | $909.43 | x |
| 2014-12-31 | $15.15 | $909.43 | x |
| 2015-12-31 | $30.28 | $909.43 | x |
| 2016-12-31 | $12.13 | $909.43 | x |
| 2017-12-31 | $2.17 | $909.43 | x |
| 2018-12-31 | $-2.22 | $909.43 | x |
| 2019-12-31 | $-3.83 | $909.43 | x |
| 2020-12-31 | $-2.77 | $909.43 | x |
| 2021-12-31 | $-5.34 | $909.43 | x |
| 2022-12-31 | $-17.72 | $909.43 | x |
| 2023-12-31 | $-28.05 | $909.43 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Endo International PLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -121.79%
- • Asset Turnover: 0.39x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-34.15%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -69.56% | -26.51% | 0.43x | 6.12x | $-853.61 Million |
| 2013 | 35.87% | 8.88% | 0.32x | 12.49x | $136.10 Million |
| 2014 | 2.46% | 2.46% | 0.22x | 4.56x | $-179.00 Million |
| 2015 | -5.03% | -9.18% | 0.17x | 3.24x | $-896.92 Million |
| 2016 | -119.33% | -80.39% | 0.28x | 5.28x | $-3.49 Billion |
| 2017 | -254.23% | -35.54% | 0.30x | 24.00x | $-1.28 Billion |
| 2018 | 0.00% | -32.63% | 0.29x | 0.00x | $-911.94 Million |
| 2019 | 0.00% | -14.50% | 0.31x | 0.00x | $-335.98 Million |
| 2020 | 0.00% | 6.34% | 0.31x | 0.00x | $248.74 Million |
| 2021 | 0.00% | -20.49% | 0.34x | 0.00x | $-488.85 Million |
| 2022 | 0.00% | -126.06% | 0.40x | 0.00x | $-2.51 Billion |
| 2023 | 0.00% | -121.79% | 0.39x | 0.00x | $-1.79 Billion |
Industry Comparison
This section compares Endo International PLC's net assets metrics with peer companies in the same industry.
Industry Context
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Endo International PLC (0Y5F) | $-6.60 Billion | -69.56% | N/A | $9.90 Million |
| Nyfosa AB (0A0K) | $2.92 Billion | 39.50% | 2.88x | $973.31 Million |
| High Templar Tech Limited (0A2T) | $12.52 Billion | 4.70% | 0.13x | $255.82 Million |
| Strategy Inc (0A7O) | $51.04 Billion | -7.54% | 0.21x | $40.17 Billion |
| NACON SASU (0A9N) | $67.54 Million | 15.85% | 1.20x | $7.64 Million |
| Antin Infrastructure Partners (0AA5) | $23.79 Million | 108.98% | 1.09x | $573.10 Million |
| Truecaller AB Series B (0AA7) | $1.41 Billion | 18.30% | 0.20x | $281.60 Million |
| Brockhaus Technologies AG (0AAW) | $254.92 Million | -6.23% | 1.68x | $74.40 Million |
| Hyloris Pharmaceuticals S.A. (0AB6) | $48.06 Million | -24.09% | 0.32x | $71.96 Million |
| Kalray S.A. (0ABT) | $28.43 Million | -41.56% | 0.67x | $33.84 Million |
| Webuild S.p.A. (0BJP) | $1.43 Billion | 10.29% | 7.14x | $1.13 Billion |